Invasive Aspergillosis after Pandemic (H1N1) 2009 | CDC EID

EID Journal Home > Volume 16, Number 6–June 2010

Volume 16, Number 6–June 2010
MEDSCAPE CME ACTIVITY
Invasive Aspergillosis after Pandemic (H1N1) 2009
Medscape, LLC is pleased to provide online continuing medical education (Medscape CME) for this journal article, allowing clinicians the opportunity to earn Medscape CME credit. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal Medscape CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at www.medscapecme.com/journal/eid; (4) view/print certificate.

Learning Objectives
Upon completion of this activity, participants will be able to:

•Describe diagnostic and management strategies for invasive aspergillosis following influenza infection.
•Identify historical outcomes of influenza-associated invasive aspergillosis.
Medscape CME Editor
Thomas J. Gryczan, Copyeditor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan has disclosed no relevant financial relationships.

Medscape CME Author
Charles P. Vega, MD, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.

Authors
Disclosures: Asma Lat, PharmD; Nahid Bhadelia, MD; Benjamin Miko, MD; and E. Yoko Furuya, MD, MSc, have disclosed no relevant financial relationships. George R. Thompson III, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Basilea Pharmaceutica Ltd.; served as a speaker or member of a speakers bureau for Merck & Co., Inc.; received grants for clinical research from Pfizer Inc.

open here to see the full-text (large):
Invasive Aspergillosis after Pandemic (H1N1) 2009 | CDC EID